Biotech · Private company
Ocera Therapeutics, Inc.
Track this companyFree. Adds Ocera Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- ornithine phenylacetatePhase 2 · Acute Episode of Overt Hepatic EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
- OCR-002 IR Oral TabletPhase 1 · CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- OCR-002 IV SolutionPhase 1 · CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- OCR-002 Oral SolutionPhase 1 · CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- OCR-002Acute Liver FailureClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- OCR002-SP103 - Oral Immediate Release StudyPHASE1 · COMPLETED · started Aug 15, 2016ClinicalTrials.gov NCT03846843 · fetched Nov 12, 2026
- Metabolism of Ornithine PhenylacetateNA · COMPLETED · started Feb 3, 2015ClinicalTrials.gov NCT03159390 · fetched Nov 12, 2026
- Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)PHASE2 · COMPLETED · started Jan 7, 2014ClinicalTrials.gov NCT01966419 · fetched Nov 12, 2026
- Emergency Use of OCR-002 in Acute Liver Failure (ALF)NO_LONGER_AVAILABLEClinicalTrials.gov NCT01634230 · fetched Nov 12, 2026